Of note, the vast majority of the 27 fusions we identified were rearranged with novel partners, with only 4 previously reported in breast cancer, including ETV6-NTRK3, CCDC6-RET, NCOA4-RET and FGFR3-TACC3 (Table 2). Here, FGFR3 is linked to breast carcinoma.